Product Name: JAK3 (1084-1098)
Product Number: PE-01AUQ90
| Size: | 200 µg | Price: | 45.00 | |
| 1 mg | $US | 90.00 | ||
| 5 mg | 211.00 |
Peptide Name: JAK3 (1084-1098)
Product Use: Services as a blocking peptide for use with the JAK3-2 rabbit polyclonal antibody (Cat. No.: AB-NK086-3) that is also available from Kinexus. The peptide sequence is located in the kinase catalytic domain last alpha-chain.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CDRPSFSALGPQLDML
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1749 Da
Peptide Purity Percent after Synthesis and Purification: 90
Product Use: Services as a blocking peptide for use with the JAK3-2 rabbit polyclonal antibody (Cat. No.: AB-NK086-3) that is also available from Kinexus. The peptide sequence is located in the kinase catalytic domain last alpha-chain.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CDRPSFSALGPQLDML
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 1749 Da
Peptide Purity Percent after Synthesis and Purification: 90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: JAK3 pan-specific antibody (Cat. No.: AB-NK086-3)
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: JAK3 pan-specific antibody (Cat. No.: AB-NK086-3)
Scientific Background: JAK3 is a protein-tyrosine kinase of the TK group and JakA family. Phosphorylation at T8, Y904 and Y980 increases phosphotransferase activity. Phosphorylation at Y939 also increases phosphotransferase activity and induces interaction with STAT5A. Phosphorylation at Y785 induces interaction with SH2-B-beta. Phosphorylation at Y981 inhibits phosphotransferase activity. It is involved in cytokine receptor-mediated intracellular signal transduction, including activation of an oncoprotein, PI3K. JAK3 may be an oncoprotein (OP). JAK3 mutations were commonly found in juvenile myelomonocytic leukemia from whole-exome sequencing studies from 13 individuals. JAK3 were hypothesized to be involved in the progression rather than the initiation of leukemia, and patients with mutated JAK3 were associated with poorer clinical results. Mutations in this gene have been found in blood, mouth, and ovarian cancers.
© Kinexus Bioinformatics Corporation 2017